查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864642

皮肤丝状菌症治疗市场按产品类型、药物类别、分销管道、最终用户和治疗用途划分－2025-2032年全球预测

Dermatophytosis Treatment Market by Product Type, Drug Class, Distribution Channel, End User, Treatment Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，皮肤丝状菌症治疗市场将成长至 214.2 亿美元，复合年增长率为 6.10%。

关键市场统计数据
基准年 2024 133.3亿美元
预计年份：2025年 141.4亿美元
预测年份 2032 214.2亿美元
复合年增长率 (%) 6.10%

全面介绍影响现代皮肤丝状菌症治疗决策的临床挑战和商业性趋势，这些挑战和趋势涉及各相关人员。

皮肤丝状菌症仍然是全球持续存在的临床挑战，其成因包括环境暴露、人口流动以及治疗方案的不断演变。患者和临床医生必须治疗方法，每种药物的製剂特性、依从性和耐受性各不相同。在此背景下，从製药企业到医院采购团队等各相关人员必须权衡临床疗效与实际因素，例如患者的依从性、就诊皮肤科医生的机会以及正在改变处方和配药方式的数位化管道的出现。

诊断技术的进步、药物类别的发展趋势以及分销管道的创新如何重塑皮肤丝状菌症的治疗选择和竞争优势

皮肤丝状菌症治疗领域正经历多重变革，这些变革正在改变治疗路径和商业模式。诊断工具的进步，包括照护现场和远端皮肤病学平台，正在缩短诊断时间，并使标靶治疗成为可能。因此，治疗路径越来越注重适合门诊和远端医疗环境的製剂和给药方案，这促使生产商调整产品系列，也促使医院和诊所重新评估其采购标准。

评估贸易政策和关税变化对皮肤丝状菌症治疗相关人员在营运、采购和商业性的影响链

2025年即将实施的关税政策环境对皮肤丝状菌症治疗药物的供应商、製造商和经销商产生了连锁反应。进口关税的增加和贸易摩擦加剧了投入成本的波动，尤其是活性药物成分和特殊辅料，这些原料的生产集中在某些地区。为了因应这种情况，製造商正在调整筹资策略，透过供应商多元化、重新评估库存政策，以及在某些情况下加快对区域生产能力的投资，来降低跨境价格波动带来的风险。

透过整合产品形态、药理分类、通路和临床应用等因素进行細項分析，优化策略定位。

深入了解细分市场的动态动态对于使产品策略与实际使用情况和分销通路特征相符至关重要。依产品类型划分，可区分口服和外用疗法。口服剂型通常包括胶囊、混悬剂和锭剂，而外用剂型则包括乳膏、凝胶、软膏和粉末。每种剂型都有其独特的依从性和应用的考虑，这些因素会影响临床偏好和患者满意度。依药物类别划分，可突显Allylamines和Azole两大药理家族。这两大家族具有不同的作用频谱和交互作用特征，这会影响医师针对不同患者族群的用药选择。

区域策略意义：监管多样性、分销管道成熟度和数位化应用如何影响各区域治疗皮肤丝状菌症的方法

区域趋势正显着影响着美洲、欧洲、中东和非洲以及亚太地区的法规环境成熟度、医疗基础设施和分销管道。在美洲，完善的医疗体系和成熟的零售药房网络支持患者广泛获取外用和口服药物，而不断普及的数位化药房则为直接与患者互动和提供患者支持服务创造了机会。该地区公立和私立医院的采购惯例对药品目录的製定和批量采购模式有重大影响。

竞争格局凸显了配方创新、供应链韧性和数位化协作对于确立皮肤丝状菌症治疗领域领导地位的重要性。

皮肤丝状菌症治疗领域的竞争格局由众多机构共同塑造，包括跨国製药公司、皮肤科专科药品生产商、学名药生产商、原料药供应商以及数位药局平台。领导企业透过配方创新提升患者依从性和皮肤生物利用度，从而实现差异化竞争；而其他企业则在成本和供应可靠性方面展开竞争，尤其是在对采购价格高度敏感的环境下。配方研发商与数位医疗服务提供者之间的合作日益重要，有助于提高患者依从性、远距离诊断和进行患者教育，这些合作构成了超越药物本身的附加价值服务的核心组成部分。

领导者可采取切实可行的策略重点，以协调配方创新、通路执行和供应链韧性，从而满足不断变化的临床和商业性需求。

产业领导者应优先考虑将临床价值提案与营运能力和通路策略结合的综合措施。首先，投资配方和以患者为中心的包装创新，以降低给药复杂性并提高患者依从性，同时将临床数据与真实世界证据研究相结合，以证明在门诊和居家医疗环境中差异化的治疗效果。其次，增强供应商多元化和区域生产选择，以降低贸易相关的成本波动，并确保按时向医院和零售网路交付产品。

我们利用透明的调查方法和混合方法检验技术，以确保在临床、商业和供应链层面获得稳健、可操作的见解。

本研究采用混合方法进行综合分析，将质性一手研究与量化二手研究结合，以得出可操作的见解。一手研究包括对皮肤科医生和全科医生、公立和私立医院的采购经理以及製造商和经销商的商业主管进行结构化访谈。这提供了关于处方行为、药物采纳决定因素和通路经济效益的实地观点。此外，还对数位药房平台进行了观察分析，并检验了供应链文檔，以了解营运限制和分销趋势。

总结性回顾摘要，临床创新、不断发展的通路和供应链韧性如何共同决定皮肤丝状菌症治疗的竞争结果。

总之，临床、商业性和政策力量的共同作用正在重塑皮肤丝状菌症的治疗模式。诊断技术的进步和远距远端医疗的普及使得疾病早期即可进行治疗，改变了外用和口服药物的选择标准，并提升了患者友善製剂的重要性。Allylamines和Azole药物分类将继续指导处方医生的选择，而剂型创新则有望在活性成分之外创造显着的差异化优势。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 越来越多地采用抗真菌联合治疗来对抗抗药性皮癣菌菌株
  • 增加对新型局部奈米载体递送系统的投资，用于定向抗真菌治疗
  • 非处方抗真菌药物销量激增，其先进配方提高了疗效。
  • 在整合数位皮肤病学平台以进行皮肤感染疾病的远距离诊断和管理方面取得了进展
  • 雷射疗法和动态疗法作为难治性皮肤丝状菌症辅助治疗的进展
  • 专注于研发疗程更短、安全性更高的口服抗霉菌药物。
  • 利用皮癣菌属的基因谱进行标靶治疗，正在涌现一些个人化治疗方法。
  • 严格的监管要求推动了新型皮肤丝状菌症病治疗药物临床试验设计的创新。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的皮肤丝状菌症病治疗市场

  • 口服
    • 胶囊
    • 暂停
    • 药片
  • 外用
    • 奶油
    • 凝胶
    • 软膏
    • 粉末

第九章 依药物类别分類的皮肤丝状菌症病治疗市场

  • Allylamines药物
  • Azole

第十章 依分销管道分類的皮肤丝状菌症治疗市场

  • 医院药房
    • 私人的
    • 民众
  • 网路药房
    • 电子处方笺
    • OTC
  • 零售药房
    • 链
    • 独立的

第十一章 依最终使用者分類的皮肤丝状菌症病治疗市场

  • 诊所
    • 皮肤科诊所
    • 一般诊所
  • 居家医疗
  • 医院
    • 私立医院
    • 公立医院

第十二章 依治疗应用分類的皮肤丝状菌症病治疗市场

  • 足癣
  • 股癣
  • 癣
  • 花斑癣

第十三章 各地区皮肤丝状菌症病治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 依组别分類的皮肤丝状菌症病治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国皮肤丝状菌症治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Novartis AG
    • GlaxoSmithKline plc
    • Bayer AG
    • Johnson & Johnson
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Limited
    • Lupin Limited
    • Viatris Inc.
    • Torrent Pharmaceuticals Limited
Product Code: MRR-7A22CB0E5C75

The Dermatophytosis Treatment Market is projected to grow by USD 21.42 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.33 billion
Estimated Year [2025] USD 14.14 billion
Forecast Year [2032] USD 21.42 billion
CAGR (%) 6.10%

An integrated introduction to the clinical challenges and commercial dynamics that underpin contemporary dermatophytosis treatment decision-making across stakeholders

Dermatophytosis remains a persistent clinical challenge globally, driven by a combination of environmental exposure, demographic mobility, and evolving treatment pathways. Patients and clinicians navigate a complex array of topical and systemic options, each with distinct formulation, compliance, and tolerability implications. Against this backdrop, stakeholders from pharmaceutical manufacturers to hospital procurement teams must reconcile clinical efficacy with real-world factors such as adherence, access to dermatology specialists, and the emergence of digital channels that change how therapy is prescribed and dispensed.

Clinical practice is adapting as diagnostic capabilities and teledermatology expand, enabling earlier recognition and differentiation among athlete's foot, jock itch, ringworm, and tinea versicolor. This shift toward earlier intervention has meaningful implications for treatment selection and duration of therapy, and it places a premium on formulations that combine ease of use with reliable pharmacologic profiles. Meanwhile, regulatory attention to generic substitution and bioequivalence remains a defining influence on product rollout strategies.

From the commercial perspective, manufacturers must integrate product design, supply chain resilience, and channel strategies to maintain competitive positioning. The interplay of oral and topical modalities, distinct drug classes with differing safety and interaction profiles, and a diversifying distribution landscape requires an integrated approach to market entry, product lifecycle management, and stakeholder engagement. This introduction frames the strategic questions that follow and prepares readers to understand how shifts in regulation, trade policy, and consumer behavior are reshaping the dermatophytosis treatment ecosystem.

How diagnostic advances, drug class dynamics, and channel innovation are reshaping therapeutic choices and competitive advantages in dermatophytosis care

The dermatophytosis landscape is experiencing several transformative shifts that alter both treatment pathways and commercial models. Advances in diagnostic tools, including point-of-care assessments and teledermatology platforms, are accelerating time-to-diagnosis and enabling targeted therapy selection. As a result, treatment pathways increasingly favor formulations and dosing regimens that align with outpatient and remote-care settings, prompting portfolio adjustments from manufacturers and revised procurement criteria within hospitals and clinics.

At the same time, drug-class dynamics are evolving. Clinical preference patterns for allylamines and azoles reflect differences in spectrum of activity, safety profile, and perceived relapse rates, prompting prescribers to refine selection criteria based on patient comorbidities and potential drug interactions. This clinical evolution is mirrored by formulation innovation that emphasizes patient convenience, enhanced dermal penetration, and tolerability, creating differentiation beyond active pharmaceutical ingredient alone.

Distribution is also in flux as online pharmacies and e-prescription models gain traction, shifting volume away from traditional retail footprints and creating new demands for digital patient support and adherence solutions. Concurrently, supply chain optimization and sourcing diversification are becoming strategic priorities in response to geopolitical pressures and raw material variability. Together, these forces are redefining competitive advantage, with companies that integrate clinical evidence, digital engagement, and resilient sourcing positioned to capture the most sustainable opportunities.

Assessing the cascading operational, procurement, and commercial consequences of trade policy and tariff shifts for dermatophytosis treatment stakeholders

The policy environment surrounding tariffs introduced in 2025 has cascading implications for suppliers, manufacturers, and distributors linked to dermatophytosis treatment. Increased import duties and trade frictions amplify input cost volatility, particularly for active pharmaceutical ingredients and specialized excipients that are produced in concentrated geographies. In response, manufacturers have adjusted procurement strategies to diversify supplier bases, re-evaluate inventory policy, and, in some cases, accelerate investments in regional manufacturing capacity to reduce exposure to cross-border pricing shocks.

Price pressures created by tariff-driven cost increases have influenced commercial decisions across distribution channels. Hospital procurement teams have responded by tightening formulary criteria and seeking procurement efficiencies, while retail and online pharmacies have reassessed margin structures and promotional tactics. The result is a renewed emphasis on cost-to-serve analysis and more rigorous contract terms with both upstream suppliers and downstream channel partners.

Regulatory and compliance burdens have also shifted in importance as trade-related documentation and customs scrutiny demand greater administrative capacity. Companies with integrated supply-chain visibility and proactive customs management have gained operational advantages. Moreover, tariffs have accelerated conversations about nearshoring and capacity redundancy; yet, these transitions require multiyear planning, capital, and regulatory alignment. Ultimately, the tariff environment has elevated resilience and flexibility as core competencies for organizations operating in the dermatophytosis treatment space.

Integrated segmentation insights linking product formats, pharmacologic classes, distribution pathways, and clinical applications to optimize strategic positioning

A nuanced understanding of segment-specific dynamics is essential to align product strategy with real-world use and channel behaviors. Product-type segmentation differentiates oral and topical therapies, with oral options typically available as capsules, suspensions, and tablets while topical formats include creams, gels, ointments, and powders, each format carrying unique adherence and application considerations that shape clinical preference and patient satisfaction. Drug-class segmentation highlights allylamines and azoles, two pharmacologic families that diverge on spectrum of activity and interaction profiles, informing prescriber choice for distinct patient populations.

Distribution channels present distinct operational and commercial imperatives. Hospital pharmacies operate across private and public settings and respond to institutional procurement cycles and formulary governance, whereas online pharmacies are split between e-prescription models and over-the-counter access, demanding digital engagement strategies and logistics optimization. Retail pharmacies differentiate between chain and independent operators, each with specific stocking, promotional, and relationship models that affect new product uptake. End-user segmentation separates clinics-both dermatology-focused and general practice-homecare settings, and hospitals divided into private and public institutions, with each care setting imposing different expectations for treatment duration, dispensing unit sizes, and patient counseling.

Treatment application segmentation distinguishes common indications such as athlete's foot, jock itch, ringworm, and tinea versicolor, and each presentation influences formulation preference, dosing duration, and the likelihood of seeking specialist care. An integrated segmentation view reveals that product design, channel strategy, and clinical positioning must be tightly coordinated to meet the heterogeneous demands of providers, payers, and patients.

Regional strategic implications showing how regulatory diversity, channel maturity, and digital adoption shape dermatophytosis treatment approaches across global regions

Regional dynamics exert clear influence on regulatory environments, healthcare infrastructure, and channel maturation across the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, established healthcare systems and a mature retail pharmacy network support broad access to both topical and oral therapies, while digital pharmacy adoption continues to expand, creating opportunities for direct-to-patient engagement and patient support services. Public and private hospital procurement practices in this region exert meaningful influence on formulary decisions and large-volume purchasing patterns.

In Europe, Middle East & Africa, regulatory complexity varies significantly across national jurisdictions, prompting multinational manufacturers to adopt differentiated registration and pricing strategies. Hospital and clinic procurement models in parts of this region emphasize cost-effectiveness and centralized purchasing, and digital health adoption is accelerating in urban centers even as supply chain constraints persist in certain markets. Meanwhile, private clinics with dermatology specialization can serve as early adopters for novel formulations and adherence-support programs.

The Asia-Pacific region presents a highly heterogeneous landscape with rapid growth in telemedicine, a high prevalence of dermatologic conditions tied to climatic factors, and an expanding manufacturing base for active ingredients and finished dosage forms. Evolving regulatory harmonization efforts and expanding online pharmacy infrastructure are enabling faster channel diversification. Across all regions, successful commercialization requires tailored regulatory engagement, nuanced channel strategies, and sensitivity to local prescribing practices and patient preferences.

Competitive landscape analysis revealing how formulation innovation, supply resilience, and digital partnerships define leadership in dermatophytosis treatment

Competitive dynamics in dermatophytosis treatment are shaped by a spectrum of organizations ranging from multinational pharmaceutical firms to specialty dermatology manufacturers, generic producers, API suppliers, and digital pharmacy platforms. Leading players differentiate through formulation innovation that enhances patient adherence and dermal bioavailability, while others compete on cost and supply reliability, particularly in settings where procurement is price-sensitive. Collaboration between formulators and digital health providers has become increasingly important to support adherence, remote diagnosis, and patient education, creating a nexus for value-added services beyond the pill or cream itself.

Supply-side actors such as contract manufacturers and API producers exert outsize influence on production flexibility and lead times, and their geographic footprint shapes cost structures and responsiveness to trade-related disruptions. Companies that have invested in quality management systems, serialization, and cold-chain-adjacent logistics for sensitive excipients have obtained differentiation in institutional procurement processes. On the commercial front, firms that deploy targeted medical affairs programs and build strong relationships with dermatology societies and clinic networks can accelerate clinical uptake and sustain product positioning.

Overall, the competitive set rewards those that combine clinical evidence generation, operational resilience, and digitally-enabled patient engagement. Strategic alliances, licensing arrangements, and selective M&A activity have been used to accelerate access to differentiated formulations, bolster distribution networks, and shore up manufacturing capacity in response to both clinical needs and macroeconomic pressures.

Actionable strategic priorities for leaders to align formulation innovation, channel execution, and supply resilience with evolving clinical and commercial demands

Industry leaders should prioritize an integrated set of actions that align clinical value proposition with operational capabilities and channel strategies. First, invest in formulation and patient-centric packaging innovations that reduce application complexity and support adherence, while pairing clinical data with real-world evidence studies to substantiate differentiated outcomes in outpatient and homecare settings. Second, strengthen supplier diversification and regional manufacturing options to mitigate trade-related cost volatility and ensure on-time delivery to hospitals and retail networks.

Next, develop channel-specific commercialization plans: build digital-first patient support and e-prescription integrations to capture growing online demand while deepening relationships with hospital pharmacy procurement teams through value-based contracting pilots and targeted educational initiatives for dermatology clinics. Concurrently, pursue partnerships with contract manufacturers or API producers to secure preferential capacity and enable rapid scale-up for high-demand formulations. Additionally, enhance medical affairs presence to support guideline inclusion and to educate prescribers on nuanced drug-class selection between allylamines and azoles.

Finally, embed agility into commercial operations by adopting advanced analytics for demand sensing, refining cost-to-serve models for each distribution pathway, and creating cross-functional rapid-response teams that can execute scenario-based supply and pricing adjustments. Executed together, these steps will improve resilience, accelerate uptake of differentiated products, and protect margin in an increasingly complex global environment.

Methodological transparency and mixed-methods validation techniques used to ensure robust, actionable insights across clinical, commercial, and supply-chain dimensions

This research synthesis leverages a mixed-methods approach that integrates primary qualitative engagement with quantitative secondary intelligence to produce actionable insights. Primary inputs included structured interviews with clinicians across dermatology and general practice, procurement leaders from private and public hospitals, and commercial executives from manufacturers and distributors, providing frontline perspectives on prescribing behavior, formulary decision drivers, and channel economics. These interviews were complemented by observational analysis of digital pharmacy platforms and supply-chain documentation to capture operational constraints and distribution trends.

Secondary analysis drew upon authoritative regulatory publications, clinical guidelines, pharmacology references, and peer-reviewed literature to validate clinical assertions and to map the differentiating profiles of allylamines and azoles. Data triangulation was applied to reconcile variations across regional practices and to ensure that segmentation frameworks accurately reflect how product format, channel, and end-user behaviors intersect. Quality assurance measures included cross-validation of interview findings with documented procurement policies and independent expert review to reduce bias.

The methodology emphasizes transparency and reproducibility. Assumptions and definitions for segmentation and regional categorizations were explicitly documented, and sensitivity checks were performed to evaluate operational scenarios under different supply-chain and policy conditions. These methodological steps ensure that the insights presented are robust, contextually grounded, and actionable for commercial and clinical decision-makers.

Concluding synthesis summarizing how clinical innovation, channel evolution, and supply-chain resilience collectively determine competitive outcomes in dermatophytosis care

In closing, the dermatophytosis treatment environment is being reshaped by converging clinical, commercial, and policy forces. Diagnostic advances and telehealth expansion are moving care earlier in the disease course, changing the calculus for topical versus oral choice and increasing the importance of patient-friendly formulations. Drug-class distinctions between allylamines and azoles continue to guide prescriber selection, and innovation in delivery formats can create meaningful differentiation beyond the active ingredient alone.

Concurrently, distribution channels are fragmenting, with online pharmacies and e-prescription models gaining share while hospital and retail procurement practices evolve under cost and compliance pressures. Trade policy and tariff developments have injected additional operational complexity, elevating the strategic importance of supplier diversification, regional manufacturing, and advanced procurement capabilities. Competitive advantage today accrues to organizations that combine clinical evidence, resilient supply chains, and digitally enabled patient engagement.

Moving forward, stakeholders should prioritize integrated strategies that align product development, channel access, and operational resilience. With clear clinical positioning and adaptive commercial execution, manufacturers and distributors can navigate policy headwinds, meet diverse patient needs, and sustain long-term value creation in the dermatophytosis treatment space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of combination antifungal therapies to combat resistant dermatophyte strains
  • 5.2. Increased investment in novel topical nanocarrier delivery systems for targeted antifungal treatment
  • 5.3. Surge in over-the-counter fungal treatments with advanced formulation technologies for improved efficacy
  • 5.4. Growing integration of digital dermatology platforms for remote diagnosis and management of skin infections
  • 5.5. Advancements in laser and photodynamic therapies as adjunct treatments for recalcitrant dermatophytosis
  • 5.6. R&D focus on oral antifungal alternatives offering shorter treatment durations and enhanced safety profiles
  • 5.7. Emergence of personalized treatment approaches using genetic profiling of dermatophyte species for targeted therapy
  • 5.8. Stringent regulatory requirements driving innovation in clinical trial designs for new dermatophytosis drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dermatophytosis Treatment Market, by Product Type

  • 8.1. Oral
    • 8.1.1. Capsules
    • 8.1.2. Suspensions
    • 8.1.3. Tablets
  • 8.2. Topical
    • 8.2.1. Creams
    • 8.2.2. Gels
    • 8.2.3. Ointments
    • 8.2.4. Powders

9. Dermatophytosis Treatment Market, by Drug Class

  • 9.1. Allylamines
  • 9.2. Azoles

10. Dermatophytosis Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
    • 10.1.1. Private
    • 10.1.2. Public
  • 10.2. Online Pharmacies
    • 10.2.1. E Prescription
    • 10.2.2. OTC
  • 10.3. Retail Pharmacies
    • 10.3.1. Chain
    • 10.3.2. Independent

11. Dermatophytosis Treatment Market, by End User

  • 11.1. Clinics
    • 11.1.1. Dermatology Clinics
    • 11.1.2. General Clinics
  • 11.2. Homecare
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Dermatophytosis Treatment Market, by Treatment Application

  • 12.1. Athlete's Foot
  • 12.2. Jock Itch
  • 12.3. Ringworm
  • 12.4. Tinea Versicolor

13. Dermatophytosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dermatophytosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dermatophytosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Bayer AG
    • 16.3.4. Johnson & Johnson
    • 16.3.5. Sanofi SA
    • 16.3.6. Teva Pharmaceutical Industries Ltd.
    • 16.3.7. Dr. Reddy's Laboratories Limited
    • 16.3.8. Lupin Limited
    • 16.3.9. Viatris Inc.
    • 16.3.10. Torrent Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DERMATOPHYTOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DERMATOPHYTOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DERMATOPHYTOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHA